Home › Liver Cancer (Hepatocellular Carcinoma) › Illinois
Liver Cancer (Hepatocellular Carcinoma) clinical trials in Illinois
20 studies for Liver Cancer (Hepatocellular Carcinoma) are looking for participants at sites in Illinois.
Cities in Illinois
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #26, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- Memorial Hospital, Shiloh
- Siteman Cancer Center - Shiloh, Shiloh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07227012National Liver Cancer Screening Trial
- Northwestern University, Chicago
RecruitingPhase 4
Ages 18 to 85 · All sexes · Updated Sep 25, 2026 · NCT06084234A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- Local Institution - 0107, Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07291076Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
- OSF St. Francis Medical Center, Peoria
RecruitingPhase 2
Ages 18 to 100 · All sexes · Updated Sep 23, 2026 · NCT07219459A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- City of Hope Chicago Cancer Center, Zion
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06427941Defining the Ablative Dose for Y-90 TARE
- Northwestern University, Chicago
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07586046Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
- RUSH University Medical Center, Chicago
- University of Chicago, Chicago
RecruitingObservational study
Ages 22 and older · All sexes · Updated Sep 11, 2026 · NCT06486454Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, Chicago
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06921785Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Lurie Children's Hospital-Chicago, Chicago
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- Carle at The Riverfront, Danville
- and 6 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT07166406A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Orchard Healthcare Research Inc, Skokie
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06330064Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
- University of Chicago Comprehensive Cancer Center, Chicago
- Carle Cancer Center NCI Community Oncology Research Program, Urbana
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05168163DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
- Rush University Medical Center, Chicago
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jul 21, 2026 · NCT07717437Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
- Northwestern University, Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 25, 2026 · NCT07042919A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Clinical Trial Site, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT06600321Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
- Northwestern University, Chicago
- Northwestern Medicine Kishwaukee Hospital, DeKalb
- Northwestern Medicine Delnor Hospital, Geneva
- and 4 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 26, 2026 · NCT05620771Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- University of Chicago Medical Center, Chicago
- Methodist Medical Center of Illinois, Peoria
RecruitingPhase 4
Ages 18 to 64 · All sexes · Updated Jan 22, 2026 · NCT04373564SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chicago
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774The Dragon PLC Trial (DRAGON-PLC)
- Rush University Medical Center, Chicago
Recruiting
Ages 18 and older · All sexes · Updated May 15, 2025 · NCT06914648From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.